82935-40-8

Upstream product

• 76-83-5 trityl chloride 
• 147-85-3 L-proline 
• 42429-27-6 L-prolinamide hydrochloride 

Downstream Products

• 98598-84-6 S(+)-2-aminomethyl-1-triphenylmethylpyrrolidine 
• 69500-64-7 (S)-2-Aminomethylpyrrolidin 
• 439097-95-7 N⁷-tert-butoxycarbonyl-2',3'-O-isopropylidene-8-oxoadenosine 5'-[methyl N-(N-trityl-L-prolyl)phosphoramidate] 
• 439097-85-5 6-N-(4,4'-dimethoxytrityl)-2',3'-O-isopropylideneadenosine 5'-[methyl N-(N-trityl-L-prolyl)phosphoramidate] 
• 722508-58-9 (S)-1-Trityl-pyrrolidine-2-carboxylic acid (2-thioxo-2λ⁵-[1,3,2]oxathiaphospholan-2-yl)-amide 
• 722508-56-7 N-(N-trityl-L-prolinamido)-2-seleno-1,3,2-oxathiaphospholane 
• 651737-64-3 C₃₄H₄₆N₃O₂P 
• 651737-66-5 N⁷-tert-butoxycarbonyl-2',3'-O-isopropylidene-8-oxoadenosine 5'-[ethyl N-(N-trityl-L-prolyl)phosphoramidate] 
• 651737-68-7 6-Amino-9-((3aR,4R,6R,6aR)-6-{isopropoxy-[((S)-1-trityl-pyrrolidine-2-carbonyl)-amino]-phosphoryloxymethyl}-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-8-oxo-8,9-dihydro-purine-7-carboxylic acid tert-butyl ester 
• 651737-70-1 N⁷-tert-butoxycarbonyl-2',3'-O-isopropylidene-8-oxoadenosine 5'-[ethyl N-(N-trityl-L-prolyl)phosphoramidothioate] 
• 651737-69-8 6-Amino-9-((3aR,4R,6R,6aR)-6-{butoxy-[((S)-1-trityl-pyrrolidine-2-carbonyl)-amino]-phosphoryloxymethyl}-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-8-oxo-8,9-dihydro-purine-7-carboxylic acid tert-butyl ester 
• 82935-51-1 (S)-2-<(3-bromo-2,6-dimethoxybenzamido)methyl>pyrrolidine 
• 651737-63-2 C₃₃H₄₄N₃O₂P 

Relevant academic research and scientific papers

Synthesis, crystal structure and antidopaminergic properties of eticlopride (FLB 131)

The synthesis of the title compounds was achieved by chlorination of 3-ethyl-6-methoxysalicylic acid followed by coupling of the corresponding salicylic acid chloride with S(-)-2-aminomethyl-1-ethylpyrrolidine and S(+)-2-aminomethyl-1-triphenylmethylpyrro

Potential Neuroleptic Agents. 2,6-Dialkoxybenzamide Derivatives with Potent Dopamine Receptor Blocking Activities

A series of some novel N-(1-ethyl-2-pyrrolidinylmethyl)benzamides was synthesized and tested for dopamine receptor blockade in vivo by the ability to block the apomorphine syndrome in the rat.Several compounds were considerably more potent than sulpiride as dopamine receptor blockers and displayed low liability to induce extrapyramidal side effects (catalepsy) in the rat.The blockade of dopamine receptor activity in vivo was mainly confined to the levorotatory isomers having the S absolute configuration.The structure-activity relationships are discussed.